FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression
FDA is requiring new warnings about the risk of serious breathing difficulties that can lead to death in patients who use gabapentanoids with opioid pain medicines or other drugs that depress the central nervous system.
